Updates and current states on liposomal vehicles for tumor targeting: precision therapy in the spotlight

Precision medicine, through theranostics, can identify various tumors and metastatic tumors for diagnostic purposes using a radioactive drug combined with a therapeutic agent. This novel approach combines diagnostic and therapeutic agents to simultaneously image and treat cancer, providing a safe and optimal way to improve cancer prognosis. Through theranostics and precision therapy, real-time monitoring of disease progression and treatment response while delivering targeted therapy to the tumor site would be possible. The synthesis and design of these agents are noteworthy as they must be biocompatible, detectable by imaging, tumor-specific, and therapeutically effective. Nanocarriers, such as liposomes, have been one of the most successful nano-biomimetic systems in drug delivery to date. Recent innovations for liposomes include the introduction of imaging probes for optical imaging, magnetic resonance imaging (MRI), positron emission tomography (PET), single-photon emission computed tomography (SPECT) in vivo, and new agents for photodynamic and photothermal therapies. Liposomes can encapsulate a range of diagnostic and therapeutic agents and have received much attention as nanocarriers for theranostic applications in the diagnosis and treatment of diseases, particularly cancer. They are one of the most promising nanocarriers in cancer theranostics for precision therapy. In this review, the use of liposomes as theranostic agents in the treatment, imaging, and diagnosis of cancer has been reviewed and some approaches have been suggested to direct them toward precision medicine.

Перевод пока недоступен